RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
  Brain Diseases
  Demyelinating Diseases
   Multiple Sclerosis
  Headache
  Memory
  Neurochemistry
  Neurodegenerative Diseases
  Regeneration
  Spinal Cord Diseases
  Stroke
  Taste
  Trigeminal Neuralgia
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Multiple Sclerosis Channel

subscribe to Multiple Sclerosis newsletter
Latest Research : Neurosciences : Demyelinating Diseases : Multiple Sclerosis

   EMAIL   |   PRINT
Naltrexone for HIV/AIDS, Cancer, and Autoimmune Diseases such as Multiple Sclerosis?

Apr 19, 2005 - 11:10:00 AM
This discovery establishes a new paradigm in medical therapy: LDN not only tends to normalize the immune system by elevating the body’s endorphin levels but also accomplishes its results with virtually no side effects or toxicity.

 
[RxPG] The drug naltrexone, which in a 50 mg dose was approved by the FDA many years ago for drug abuse and for alcoholism, in less than one-tenth that dosage boosts the immune system and thus helps fight any disease that is characterized by inadequate immune function.

Investigators mounting successful clinical trials, along with physicians and patients utilizing low dose naltrexone (LDN), will make panel presentations on June 11th at a conference to be held at the New York Academy of Sciences. The keynote speaker will be Bernard Bihari, MD, a Manhattan physician and the discoverer of the clinical effects of LDN.

This discovery establishes a new paradigm in medical therapy: LDN not only tends to normalize the immune system by elevating the body’s endorphin levels but also accomplishes its results with virtually no side effects or toxicity.

Two pilot studies have recently been completed, one for Crohn’s disease and one for multiple sclerosis (MS), and the principal investigators, respectively from Hershey Medical Center at Penn State and from Dr. Evers Clinic, a hospital for neurological disease in Germany, will be present.

The promise of LDN is significant because:

(a) it can halt diseases (e.g., MS and other autoimmune diseases, HIV, and many cancers) where there are no effective treatment options;

(b) it provides successful treatment while being virtually free of side effects or toxicity; and

(c) were it produced in a developing country, this generic drug would offer an extremely inexpensive ($10 per year) HIV treatment, one that does not require close supervision by health professionals—the patient need only take one small capsule each night at bedtime.



On the web: Comprehensive Details Regarding LDN 

Advertise in this space for $10 per month. Contact us today.


Related Multiple Sclerosis News
Smoking associated with rapid progression of multiple sclerosis
Testosterone may help men with multiple sclerosis
Age of onset but not severity of Multiple Sclerosis inherited from parents
Cause of nerve fiber damage in multiple sclerosis identified
Fampridine may hold promise for treating Multiple Sclerosis
CNS can send out signals to invite autoimmune attacks
Natalizumab Re-approved for Relapsing Multiple Sclerosis
Efficacy in relapse rate reduction beyond five years shown for interferon beta 1b in Multiple Sclerosis
Systematic Review Questions Accuracy of MRI in Multiple Sclerosis
Statins could prove useful in treating MS

Subscribe to Multiple Sclerosis Newsletter

Enter your email address:


 Additional information about the news article
The conference will be held on June 11, 2005 from 9am to 4pm at the New York Academy of Sciences, located at 2 East 63rd Street, between Fifth and Madison Avenues in Manhattan.

For additional information, comprehensive details regarding LDN are provided at www.ldninfo.org. The website www.remedyfind.com includes independent ratings of LDN by people with MS, who rank it far higher than any other MS medical treatment; and http://ldners.org/surveys.htm displays results of surveys of hundreds of people with MS, who are reporting striking reductions in disease progression as well as marked functional improvement on LDN alone.

Contact Information:
David Gluck, MD
212-734-5109
http://www.ldninfo.org
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)